WO2007042669A3 - Derivatives of 4-amino-quinazoline, preparation method thereof and use of same in therapeutics - Google Patents
Derivatives of 4-amino-quinazoline, preparation method thereof and use of same in therapeutics Download PDFInfo
- Publication number
- WO2007042669A3 WO2007042669A3 PCT/FR2006/002286 FR2006002286W WO2007042669A3 WO 2007042669 A3 WO2007042669 A3 WO 2007042669A3 FR 2006002286 W FR2006002286 W FR 2006002286W WO 2007042669 A3 WO2007042669 A3 WO 2007042669A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkylene
- alkyl
- aryl
- optionally substituted
- nrarb
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- DRYRBWIFRVMRPV-UHFFFAOYSA-N quinazolin-4-amine Chemical class C1=CC=C2C(N)=NC=NC2=C1 DRYRBWIFRVMRPV-UHFFFAOYSA-N 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 11
- 229910003827 NRaRb Inorganic materials 0.000 abstract 7
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- -1 cycloprop-1,2-diyl Chemical group 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The invention relates to derivatives of 4-amino-quinazoline, having general formula (I) wherein: A, B = C1-4-alkylene which is optionally substituted; L = a single bond, C1-2-alkylene, -CH=CH- or -C=C-; groups C1-2-alkylene and -CH=CH- which are optionally substituted, or L = cycloprop-1,2-diyl; R = H, C1-5-alkyl, C1-3-fluoroalkyl, C3-6-cycloalkyl, -C(O)C1-3-alkyl, C1-3-alkylene-C3-6-cycloalkyl, -CH2-C≡CH, C2-4-alkylene-NRaRb, C1-3-alkylene-X-C1-3-alkyl, in which X = O, SO2; R1 = aryl or heteroaryl which are optionally substituted; R2 and R3 = H, C1-3-alkyl or C1-3-fluoroalkyl, or R2 and R3 together form a cycloprop-1,1-diyl; R4 = H, C1-5-alkyl, C1-3- fluoroalkyl, C1-5-alkoxy, -SF5, C1-3-alkylene-X-C1-3-alkyl, in which X = O or SO2, C1-5-alkylene- NRaRb, an aryl or a heteroaryl which are optionally substituted; R5 = H, halogen, C1-5-alkyl, C1-3-fluoroalkyl, C1-5-alkoxy, C3-6-cycloalkyl, C1-3-alkylene-C3-6-cycloalkyl, C1-3-alkylene-O-C1-3-alkyl, C1-3-alkylene-(OH), C1-3-alkylene-X-C1-3-alkyl, in which X = S, SO or SO2, or R5 = -NRaRb, C1-3-alkylene-NRaRb, aryl, C1-3-alkylene-aryl, -O-aryl, C1-3-alkylene-O-aryl, C1-3-alkylene-O-C1-3-alkylene-aryl, heteroaryl or C1-3-alkylene-heteroaryl which are optionally substituted, or R5 = heterocycle which is optionally substituted by C1-3-alkyl, -C(O)C1-3-alkyl, -C(O)C1-3-fluoroalkyl, C1-3-alkylene-C3-6-cycloalkyl, C1-3-alkylene-aryl, C1-3-alkylene-heteroaryl which are optionally substituted; R7 = H, halogen, C1-5-alkyl, C1-13-fluoroalkyl, C1-5-alkoxy, -COOH, -C(O)O-C1-3-alkyl, C1-3-fluoroalkoxy, C1-3-alkylene-(OH), -NO2, -CN, -X-C1-3-alkyl, in which X represents S, SO or SO2, or R7 = -NRaRb, C1-3-alkylene-NRaRb, -C(O)-NRaRb, -C(O)-C1-3-alkyl, aryl, -O-aryl or heteroaryl which are optionally substituted; in the form of a base, an acid addition salt, a hydrate or a solvate. The invention also relates to the method of preparing said derivatives and to the use of same in therapeutics.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0510409A FR2891829A1 (en) | 2005-10-12 | 2005-10-12 | 4-AMINO-QUINAZOLINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF |
| FR0510409 | 2005-10-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2007042669A2 WO2007042669A2 (en) | 2007-04-19 |
| WO2007042669A3 true WO2007042669A3 (en) | 2007-05-31 |
Family
ID=36645639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/FR2006/002286 WO2007042669A2 (en) | 2005-10-12 | 2006-10-11 | Derivatives of 4-amino-quinazoline, preparation method thereof and use of same in therapeutics |
Country Status (5)
| Country | Link |
|---|---|
| AR (1) | AR056688A1 (en) |
| FR (1) | FR2891829A1 (en) |
| TW (1) | TW200732308A (en) |
| UY (1) | UY29857A1 (en) |
| WO (1) | WO2007042669A2 (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007283113A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use |
| AU2009249246A1 (en) * | 2008-05-22 | 2009-11-26 | Allergan, Inc. | Bicyclic compounds having activity at the CXCR4 receptor |
| WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| MX2012001729A (en) | 2009-08-26 | 2012-06-13 | Sanofi Sa | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use. |
| EP2683700B1 (en) | 2011-03-08 | 2015-02-18 | Sanofi | Tetra-substituted oxathiazine derivatives, method for their preparation, their usage as medicament and medicament containing same and its use |
| EP2683705B1 (en) | 2011-03-08 | 2015-04-22 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2012120053A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2012120052A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
| US10588907B2 (en) | 2015-06-04 | 2020-03-17 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| AU2017235462B2 (en) | 2016-03-16 | 2021-07-01 | Kura Oncology, Inc. | Bridged bicyclic inhibitors of menin-MLL and methods of use |
| MX388839B (en) | 2016-03-16 | 2025-03-20 | Kura Oncology Inc | Substituted inhibitors of menin-mll and methods of use |
| US11944627B2 (en) | 2017-03-24 | 2024-04-02 | Kura Oncology, Inc. | Methods for treating hematological malignancies and Ewing's sarcoma |
| US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| WO2019060365A1 (en) | 2017-09-20 | 2019-03-28 | Kura Oncology, Inc. | Substituted inhibitors of menin-mll and methods of use |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1984001151A1 (en) * | 1982-09-24 | 1984-03-29 | Beecham Group Plc | Amino-azabicycloalkyl derivatives as dopamine antagonists |
| GB2295387A (en) * | 1994-11-23 | 1996-05-29 | Glaxo Inc | Quinazoline antagonists of alpha 1c adrenergic receptors |
| WO2003028641A2 (en) * | 2001-10-01 | 2003-04-10 | Taisho Pharmaceutical Co., Ltd. | Mch receptor antagonists |
| WO2003106452A2 (en) * | 2002-06-12 | 2003-12-24 | Millennium Pharmaceuticals, Inc. | Antagonists of melanin concentrating hormone receptor |
| WO2004052371A2 (en) * | 2002-12-11 | 2004-06-24 | 7Tm Pharma A/S | Cyclic quinoline compounds for use in mch receptor related disorders |
| WO2004078733A1 (en) * | 2003-03-03 | 2004-09-16 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
| WO2006071095A1 (en) * | 2004-12-31 | 2006-07-06 | Sk Chemicals Co., Ltd. | Quinazoline derivatives for the treatment and prevention of diabetes and obesity |
-
2005
- 2005-10-12 FR FR0510409A patent/FR2891829A1/en not_active Withdrawn
-
2006
- 2006-10-11 WO PCT/FR2006/002286 patent/WO2007042669A2/en active Application Filing
- 2006-10-11 AR ARP060104457A patent/AR056688A1/en not_active Application Discontinuation
- 2006-10-12 UY UY29857A patent/UY29857A1/en unknown
- 2006-10-12 TW TW095137552A patent/TW200732308A/en unknown
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1984001151A1 (en) * | 1982-09-24 | 1984-03-29 | Beecham Group Plc | Amino-azabicycloalkyl derivatives as dopamine antagonists |
| GB2295387A (en) * | 1994-11-23 | 1996-05-29 | Glaxo Inc | Quinazoline antagonists of alpha 1c adrenergic receptors |
| WO2003028641A2 (en) * | 2001-10-01 | 2003-04-10 | Taisho Pharmaceutical Co., Ltd. | Mch receptor antagonists |
| WO2003106452A2 (en) * | 2002-06-12 | 2003-12-24 | Millennium Pharmaceuticals, Inc. | Antagonists of melanin concentrating hormone receptor |
| WO2004052371A2 (en) * | 2002-12-11 | 2004-06-24 | 7Tm Pharma A/S | Cyclic quinoline compounds for use in mch receptor related disorders |
| WO2004078733A1 (en) * | 2003-03-03 | 2004-09-16 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
| WO2006071095A1 (en) * | 2004-12-31 | 2006-07-06 | Sk Chemicals Co., Ltd. | Quinazoline derivatives for the treatment and prevention of diabetes and obesity |
Also Published As
| Publication number | Publication date |
|---|---|
| UY29857A1 (en) | 2007-05-31 |
| TW200732308A (en) | 2007-09-01 |
| AR056688A1 (en) | 2007-10-17 |
| FR2891829A1 (en) | 2007-04-13 |
| WO2007042669A2 (en) | 2007-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007042669A3 (en) | Derivatives of 4-amino-quinazoline, preparation method thereof and use of same in therapeutics | |
| WO2009025983A3 (en) | Method for preparing 5-haloalkyl-4,5-dihydroisoxazole derivatives | |
| NO20074093L (en) | Methods for Preparing Glucopyranosyl-Substituted Benzyl-Benzene Derivatives and Intermediates | |
| WO2007042660A3 (en) | Substituted 1-amino-phthalzine derivatives, preparation and therapeutic use thereof | |
| TW200833690A (en) | 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | |
| WO2006108695A3 (en) | Sulfoximine-pyrimidine macrocycles and the salts thereof , a process for making them, and their pharmaceutical use against cancer | |
| WO2009156861A3 (en) | Substituted pyrimidone derivatives | |
| EA200501477A1 (en) | DERIVATIVES OF PIPERIDINYL- AND PIPERASINILYLKYLKARBAMATS, METHODS FOR THEIR PRODUCTION AND USE OF THEM IN THERAPY | |
| JP2009530268A5 (en) | ||
| WO2010089510A3 (en) | Derivatives of azaspiranyl-alkylcarbamates of 5-member heterocyclic compounds, preparation thereof and therapeutic use thereof | |
| TW200637860A (en) | Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same | |
| CO6460742A2 (en) | DERIVATIVES OF CICLOPENTA [C] PIRROLILALQUILCARBAMATOS OF 5-MEMBER HETEROCICLES, ITS PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | |
| WO2008009750A3 (en) | Macrocyclic compounds useful as bace inhibitors | |
| DE60312029D1 (en) | PROCESS FOR PREPARING C-7 SUBSTITUTED 5-ANDROSTENDS | |
| TW200617000A (en) | Methods of making 2,6-diaryl piperidine derivatives | |
| WO2008003855A3 (en) | Use of 2-benzoyl-imidazopyridines in therapeutics | |
| DE602004004679D1 (en) | PROCESS FOR PREPARING THE HEMICALCIUM SALT OF (E) -7-A4- (4-FLUORO-PHENYL) -6-ISOPROPYL-2-EMETHYL (METHYLSULFONYL) AMINO-PYRIMIDIN-5-YLÜ (3R, 5S) -3,5-DIHYDROXY-6-HEPTIC ACID | |
| WO2006066957A3 (en) | Sulfonamido-macrocycles as tie2 inhibitors | |
| WO2009106750A3 (en) | Derivatives of 6-heterocyclic-imidazo[l,2-a]pyrroine-2-carboxamides, preparation thereof and therapeutic application thereof | |
| JP2012503653A5 (en) | ||
| WO2006066044A3 (en) | Processes for producing 4-aminoquinazolines | |
| SI1915375T1 (en) | DERIVATIVES OF 5-PYRIDINYL-1-AZABICYCLO?á3.2.1?åOCTANE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | |
| WO2006066956A3 (en) | Sulfonamido-macrocycles as tie2 inhibitors | |
| WO2010067010A3 (en) | Derivatives of morphine-6-glucuronide, preparation method thereof and use of same in therapeutics | |
| DE602006003879D1 (en) | PROCESS FOR THE PREPARATION OF ENANTIOMERINE PURE 4-PYRROLIDINOPHENYL-BENZYL ETHER DERIVATIVES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 06820187 Country of ref document: EP Kind code of ref document: A2 |